Patrys Limited announced that it has appointed an experienced US-based biotechnology executive, Dr. Peter Ordentlich, to its Scientific Advisory Board (SAB). Dr. Peter Ordentlich completed a PhD in Immunology at the University of Pennsylvania and a Post-Doc at the Salk Institute for Biological Studies before joining X-Ceptor Therapeutics, a discovery stage biotechnology company focused on the identification of novel therapeutics for cardiovascular and oncology indications. Dr. Ordentlich spent five years as a research scientist leading multiple lead discovery and optimization projects at X-Ceptor Therapeutics, which was acquired by Exelixis in 2004. In 2005 Dr. Ordentlich co-founded Syndax Pharmaceuticals, a NASDAQ-listed, clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies with three clinical stage assets, where he is currently the Chief Scientific Officer.